On Nov. 18, 2020, Todos Medical announced positive clinical proof of concept data from its lab-based rapid SARS-CoV-2 3CL protease diagnostic assay in collaboration with its COVID Antigen Test Killer joint venture partner NLC Pharma.

The data generated by NLC Pharma in Israel produced 100% sensitivity and 100% specificity in PCR-confirmed positive and negative COVID-19 patient samples. The team has begun gathering additional clinical data to submit an emergency use authorization (EUA) to the U.S. Food & Drug Administration ( FDA) for its lab-based test to be distributed through Todosﾒ existing lab distribution channels.